Investigational drug · Phase 3
VEGF bispecific antibody
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Squamous Non-small-cell Lung Cancer, Non-squamous Non-small Cell Lung Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
89
Any phase or sponsor naming "VEGF bispecific antibody"
First trial start
2026
Oct 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VEGF bispecific antibody", any sponsor or status.
Conditions studied
As listed on its trial records.
- Squamous Non-small-cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "VEGF bispecific antibody" as an intervention, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)Pivotal-lookingRecruiting
BioNTech SEIndustry
NCT06712316 · 1,580 participants (planned) · Start Jan 7, 2025 · Primary completion Jan 2029
Drug: Pumitamig; Pembrolizumab and 3 more · For: Non-small Cell Lung Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Concord, California · 366 sites in all
BioNTech SEIndustry
NCT07070232 · 1,438 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: BNT326; Pumitamig and 2 more · For: Advanced Solid Tumor
Sites: Phoenix, Arizona; San Francisco, California; Hartford, Connecticut · 79 sites in all
- A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07865910 · 1,438 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 30, 2030
Drug: Investigational drug: HLX37 dose1, IV, Q3W; PEMBROLIZUMAB (alone or when added to a regimen above) and 4 more · For: NSCLC (Advanced Non-small Cell Lung Cancer)
Sites: Hefei, China; Beijing, China; Chongqing, China · 16 sites in all
- A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)Pivotal-lookingRecruiting
BioNTech SEIndustry
NCT07111520 · 880 participants (planned) · Start Sep 22, 2025 · Primary completion Nov 2028
Drug: BNT326; Pumitamig · For: Non-small Cell Lung Cancer
Sites: Los Angeles, California; Stanford, California; New Haven, Connecticut · 87 sites in all
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerPivotal-lookingRecruiting
BioNTech SEIndustry
NCT06712355 · 621 participants (planned) · Start Feb 3, 2025 · Primary completion Apr 2029
Drug: Pumitamig; Atezolizumab and 2 more · For: Extensive-stage Small-cell Lung Cancer
Sites: Tucson, Arizona; Clermont, Florida; Palm Bay, Florida · 225 sites in all
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07307053 · 600 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 31, 2029
Drug: BL-B01D1; VSV injection and 18 more · For: Rare Malignant Neoplasm; Advanced Solid Tumors; Metastatic Solid Tumors
- A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerPivotal-lookingRecruiting
BioNTech SEIndustry
NCT06892548 · 594 participants (planned) · Start May 2, 2025 · Primary completion Sep 2028
Drug: BNT324; BNT327 · For: Advanced Lung Cancer
Sites: Phoenix, Arizona; Beverly Hills, California; Los Angeles, California · 91 sites in all
- JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerPivotal-lookingNot yet recruiting
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
NCT07823348 · 560 participants (planned) · Start Oct 8, 2026 · Primary completion Oct 30, 2029
Drug: JS207; JS007 and 2 more · For: Hepatocellular Carcinoma
Sites: Harbin, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Acquired immune-mediated thrombotic thrombocytopenic purpura with severe cholestatic liver injury and reversible acute kidney injury after ivonescimab-containing chemoimmunotherapy: a case report and literature review.
Chen Q, Song X, Zhang M, et al. · Front Immunol 2026
- Neoadjuvant PD-1/VEGF bispecific antibody combined with chemotherapy for locally advanced pulmonary lymphoepithelioma-like carcinoma achieving pathological complete response: a case report and literature review.
You Y, Yang M, Chen Z, et al. · Front Immunol 2026
- Severe IL-6-dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report.
Yang F, Xuan L, Li J · Front Oncol 2026
Also in development for Squamous Non-small-cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.